<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Boycott Novartis &#187; TRIPS</title>
	<atom:link href="http://novartisboycott.org/topics/trips/feed/" rel="self" type="application/rss+xml" />
	<link>http://novartisboycott.org</link>
	<description>Campaign against the Swiss Pharmacuetical Company</description>
	<lastBuildDate>Fri, 27 Apr 2012 03:22:59 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>It&#8217;s a relief for the HIV-infected</title>
		<link>http://novartisboycott.org/its-a-relief-for-the-hiv-infected/</link>
		<comments>http://novartisboycott.org/its-a-relief-for-the-hiv-infected/#comments</comments>
		<pubDate>Wed, 09 Jul 2008 04:53:20 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Article]]></category>
		<category><![CDATA[TRIPS]]></category>

		<guid isPermaLink="false">http://novartisboycott.org/?p=36</guid>
		<description><![CDATA[Deccan Herald » Edit Page » Detailed Story IN PERSPECTIVE By Gopal Dabade Deccan Herald If patents are granted to a company, the price of the drug would be beyond the reach of the masses. Just a few days back &#8230; <a href="http://novartisboycott.org/its-a-relief-for-the-hiv-infected/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://novartisboycott.org/its-a-relief-for-the-hiv-infected/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cancer drug patent case takes new turn</title>
		<link>http://novartisboycott.org/cancer-drug-patent-case-takes-new-turn/</link>
		<comments>http://novartisboycott.org/cancer-drug-patent-case-takes-new-turn/#comments</comments>
		<pubDate>Sat, 23 Jun 2007 08:39:09 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Patent Litigation]]></category>
		<category><![CDATA[TRIPS]]></category>

		<guid isPermaLink="false">http://novartisboycott.org/cancer-drug-patent-case-takes-new-turn/</guid>
		<description><![CDATA[Times of India, June 19, 2007 The much-awaited appeal proceedings in a cancer drug patent case could not begin on Monday as Swiss major Novartis AG, turning the tables on the government, raised a conflict-of-interest objection to the composition of &#8230; <a href="http://novartisboycott.org/cancer-drug-patent-case-takes-new-turn/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://novartisboycott.org/cancer-drug-patent-case-takes-new-turn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis may suffer jolt in Glivec case</title>
		<link>http://novartisboycott.org/novartis-may-suffer-jolt-in-glivec-case/</link>
		<comments>http://novartisboycott.org/novartis-may-suffer-jolt-in-glivec-case/#comments</comments>
		<pubDate>Thu, 21 Jun 2007 08:43:03 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Article]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Patent Litigation]]></category>
		<category><![CDATA[TRIPS]]></category>

		<guid isPermaLink="false">http://novartisboycott.org/novartis-may-suffer-jolt-in-glivec-case/</guid>
		<description><![CDATA[Financial Express, June 20, 2007 The Intellectual Property Appellate Board (IPAB), which has been formed to give a verdict on various patent cases across the country, may reject Novartis objection on the presence of S Chandrasekharan, the former patent controller, &#8230; <a href="http://novartisboycott.org/novartis-may-suffer-jolt-in-glivec-case/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://novartisboycott.org/novartis-may-suffer-jolt-in-glivec-case/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patent act of India faces challenge</title>
		<link>http://novartisboycott.org/patent-act-of-india-faces-challenge/</link>
		<comments>http://novartisboycott.org/patent-act-of-india-faces-challenge/#comments</comments>
		<pubDate>Tue, 10 Apr 2007 05:28:46 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Patent Litigation]]></category>
		<category><![CDATA[TRIPS]]></category>

		<guid isPermaLink="false">http://novartisboycott.org/patent-act-of-india-faces-challenge/</guid>
		<description><![CDATA[In a rather predictable move, Novartis, the swiss multinational company which holds patent for a many medicines used for treating camcer, leukemia, malaria and many others including the the anti retro-viral AIDS medicine has challenged the contentious Section 3(d) introduced &#8230; <a href="http://novartisboycott.org/patent-act-of-india-faces-challenge/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://novartisboycott.org/patent-act-of-india-faces-challenge/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

